Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain
Portfolio Pulse from
Dogwood Therapeutics has begun dosing the first patient in its Phase 2b trial for Halneuron®, a treatment for chemotherapy-induced neuropathic pain (CINP). This opioid-free therapy targets a $1.5 billion global market.
March 18, 2025 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Dogwood Therapeutics has initiated a Phase 2b trial for Halneuron®, an opioid-free treatment for chemotherapy-induced neuropathic pain, addressing a $1.5 billion market.
The initiation of a Phase 2b trial for Halneuron® is a significant step for Dogwood Therapeutics, as it targets a large market with an opioid-free solution. Successful trial results could lead to increased investor interest and potential stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100